Neopharmed Gentili
Healthcare
HQ: Milano, Italy
Investors: 5 (4 current, 1 exited)
An Italian pharmaceutical company focused on the commercialization of high-value therapeutic solutions.
Investors (5)
| Fund | Status | Entry Date | Stage | Source |
|---|---|---|---|---|
| Ardian | Current | 2022 | - | Website |
| Anima Alternative SGR | Current | - | - | Website |
| Narval Investimenti | Current | - | - | Website |
| Renaissance Partners | Current | - | - | Website |
| Green Arrow Capital SGR | Exited | - | - | Website |
Get these signals delivered weekly
Deals, exits, fundraises, and key hires from funds active in Italy — straight to your inbox.
Get SignalsSignals (1)
2025-06-27
Neopharmed Gentili signed an agreement to acquire Bio Cryst's ORLADEYO business in Europe for up to $264M, including $250M upfront and milestone payments
Source: BioCryst